SPAC9.11 Antibody

What experimental applications is the SPAC9.11 antibody validated for?

The SPAC9.11 antibody has been validated primarily for enzyme-linked immunosorbent assay (ELISA) and Western blotting (WB) applications. When selecting this antibody for your research, note that it has undergone antigen affinity purification to ensure specificity for the SPAC9.11 protein in Schizosaccharomyces pombe (strain 972 / ATCC 24843). Unlike some antibodies with broader cross-reactivity profiles, this antibody is specifically designed for fission yeast research applications . For researchers planning to use this antibody in other applications such as immunoprecipitation or immunohistochemistry, additional validation steps would be necessary.

What is the recommended protocol for antibody pull-down experiments using SPAC9.11 antibody in fission yeast?

For antibody pull-down experiments with SPAC9.11 in Schizosaccharomyces pombe, follow this methodological approach:

• Cell preparation: Grow 50-100 ml of fission yeast culture to mid-log phase (OD600 of 0.5-0.8)

• Cell lysis: Harvest cells by centrifugation and lyse using glass bead disruption in appropriate lysis buffer (containing protease inhibitors)

• Pre-clearing: Incubate cell lysate with protein A or G beads for 1 hour at 4°C

• Immunoprecipitation: Add 2-5 μg of SPAC9.11 antibody to pre-cleared lysate and incubate overnight at 4°C with gentle rotation

• Bead binding: Add protein A/G beads and incubate for 2-4 hours at 4°C

• Washing: Wash beads 4-5 times with lysis buffer

• Elution: Elute bound proteins by boiling in SDS sample buffer

This approach has been demonstrated to be effective for detecting protein-protein interactions in fission yeast . For optimal results, include appropriate controls including a non-specific IgG antibody control and input sample validation.

How can I verify the specificity of the SPAC9.11 antibody in my experimental system?

To verify SPAC9.11 antibody specificity:

• Perform Western blot using wild-type and SPAC9.11 deletion mutant strains

• Include peptide competition assays where the antibody is pre-incubated with excess recombinant SPAC9.11 protein

• Validate results using orthogonal methods such as mass spectrometry identification of immunoprecipitated proteins

• Test cross-reactivity with closely related proteins

The search results indicate that antibody specificity validation is a critical step, particularly for polyclonal antibodies. For example, in studies with other antibodies like anti-SpCas9, researchers employed multiple validation techniques to ensure specificity . When working with fission yeast proteins, it's essential to verify that the antibody recognizes the correct molecular weight target and doesn't cross-react with other proteins in the yeast proteome.

How can I use the SPAC9.11 antibody to investigate protein-chromatin interactions in fission yeast?

To investigate SPAC9.11 interactions with chromatin:

• Chromatin Immunoprecipitation (ChIP): Adapt standard ChIP protocols using the SPAC9.11 antibody to identify genomic binding sites. Crosslink cells with formaldehyde (1-1.5%, 10-15 min), lyse cells, sonicate chromatin to 200-500 bp fragments, immunoprecipitate with SPAC9.11 antibody, reverse crosslinks, purify DNA, and analyze by qPCR or sequencing.

• Co-Immunoprecipitation with Chromatin Modifiers: Based on findings with related proteins, SPAC9.11 may interact with chromatin-modifying complexes like the Clr6 histone deacetylase complex . Design co-IP experiments targeting known chromatin modifiers in fission yeast:

• Sequential ChIP: For complex interactions, perform sequential ChIP (re-ChIP) first with SPAC9.11 antibody, then with antibodies against histone modifications or other chromatin factors.

Research on related chromatin-associated factors suggests SPAC9.11 may be involved in the regulation of gene expression through interactions with splicing machinery components and chromatin modifiers .

What are the technical considerations when using SPAC9.11 antibody in combination with high-throughput sequencing approaches?

When combining SPAC9.11 antibody with high-throughput sequencing:

• Antibody Efficiency Validation: Before proceeding with costly sequencing, validate immunoprecipitation efficiency using qPCR for regions expected to be bound by SPAC9.11 or its complex.

• Input Normalization: Always prepare matched input controls from the same chromatin preparation for accurate normalization.

• Sequencing Considerations:

  • Use appropriate library preparation methods (consider whether protein connects to DNA directly or via RNA)

  • Include spike-in controls for normalization across samples

  • Generate sufficient sequencing depth (minimum 20 million reads for ChIP-seq)

  • Employ stringent peak calling parameters to minimize false positives

• Validation of Findings: Confirm key results using orthogonal approaches such as targeted ChIP-qPCR or reporter assays.

Based on related studies, such as those investigating splicing factors like Rbm10 in fission yeast, these approaches can reveal unexpected connections between chromatin-associated factors and cellular processes .

How can I determine if SPAC9.11 interacts with the Clr6 histone deacetylase complex in my experimental system?

To investigate SPAC9.11 interactions with Clr6:

• Reciprocal Co-immunoprecipitation:

  • Perform IP with SPAC9.11 antibody and blot for Clr6

  • Perform IP with Clr6 antibody and blot for SPAC9.11

  • Include appropriate controls (IgG, input, deletion strains)

• Proximity Ligation Assay (PLA):

  • Use SPAC9.11 and Clr6 antibodies in combination

  • Visualize interactions as fluorescent spots if proteins are in close proximity

• Mass Spectrometry Analysis:

  • Immunoprecipitate with SPAC9.11 antibody

  • Analyze by liquid chromatography-tandem mass spectrometry (LC-MS/MS)

  • Quantify Clr6 and other complex components in the immunoprecipitate

• Functional Validation:

  • Compare phenotypes of SPAC9.11 and Clr6 mutants

  • Assess histone acetylation levels in SPAC9.11 mutants

  • Perform epistasis analysis with double mutants

Recent research has shown that various proteins in fission yeast interact with the Clr6 histone deacetylase complex, which is involved in heterochromatin assembly . Based on patterns observed with other chromatin-associated factors, investigators should consider testing for co-localization at specific genomic regions using sequential ChIP approaches.

What is known about SPAC9.11's function in relation to heterochromatin formation in fission yeast?

While specific information about SPAC9.11's role in heterochromatin formation is limited in the search results, we can draw parallels with related proteins in fission yeast:

Heterochromatin in fission yeast is established and maintained through several pathways:

• RNAi-dependent pathway: Involves transcription of heterochromatic regions, processing by Dicer, and recruitment of chromatin modifiers

• RNAi-independent pathway: Involves sequence-specific DNA binding factors

• Histone deacetylation: Critical for heterochromatin formation, primarily through the Clr6 complex

If SPAC9.11 interacts with the Clr6 histone deacetylase complex as suggested by patterns seen with other chromatin-associated factors , it may contribute to heterochromatin assembly by:

• Recruiting histone deacetylases to specific genomic regions

• Stabilizing protein complexes at heterochromatic regions

• Facilitating the processing of non-coding RNAs involved in heterochromatin formation

Researchers investigating SPAC9.11's function should examine its localization relative to known heterochromatic regions and assess heterochromatin stability in SPAC9.11 mutants using assays for silencing, histone modifications, and chromatin accessibility.

How do I interpret contradictory results between antibody-based detection methods and genetic approaches when studying SPAC9.11?

When faced with contradictory results:

• Evaluate antibody specificity:

  • Confirm the antibody recognizes endogenous SPAC9.11 at expected molecular weight

  • Test antibody in SPAC9.11 deletion or knockdown strains

  • Consider epitope accessibility in different experimental conditions

• Assess genetic approach limitations:

  • Verify gene deletions/mutations by sequencing

  • Consider potential genetic compensation mechanisms

  • Evaluate for synthetic interactions with related genes

• Reconciliation approaches:

  • Use complementary methods (e.g., tagged SPAC9.11 constructs)

  • Perform rescue experiments with wild-type SPAC9.11

  • Examine context-dependent effects (cell cycle, stress conditions)

  • Consider post-translational modifications affecting antibody recognition

• Methodological controls:

  • Include positive controls for antibody function

  • Use orthogonal detection methods (mass spectrometry)

  • Test different fixation/extraction conditions that may affect epitope recognition

Research on related proteins in fission yeast has shown that discrepancies can arise due to context-dependent protein functions or conditional interactions, as observed with splicing factors and chromatin regulators .

How can I integrate SPAC9.11 antibody data with genome-wide studies of chromatin structure and gene expression?

To integrate antibody-based SPAC9.11 data with genomic approaches:

• Correlation analysis: Compare SPAC9.11 binding patterns with:

  • Histone modification profiles (H3K9me, H3K4me, H3K36me)

  • Transcription factor binding sites

  • RNA polymerase II occupancy

  • Nucleosome positioning

• Functional genomics approaches:

  • Perform differential expression analysis in SPAC9.11 mutants

  • Identify direct vs. indirect effects using rapid depletion approaches

  • Conduct synthetic genetic array (SGA) analysis to identify genetic interactions

• Visualization and computational analysis:

  • Generate genome browser tracks integrating multiple datasets

  • Employ machine learning approaches to identify patterns

  • Use gene ontology and pathway enrichment analysis to contextualize findings

Studies in fission yeast have successfully employed integrated approaches to understand the functions of chromatin-associated factors, revealing connections between seemingly disparate processes like RNA splicing and heterochromatin assembly .

How can I optimize immunoprecipitation conditions to detect weak or transient interactions with SPAC9.11?

To detect weak or transient interactions:

• Crosslinking optimization:

  • Test formaldehyde crosslinking (0.1-1%, 5-15 minutes)

  • Try protein-specific crosslinkers (DSP, DTBP)

  • Optimize crosslinking time and temperature

• Buffer modifications:

  • Reduce salt concentration to preserve weak interactions (50-100mM NaCl)

  • Add protein stabilizers (5-10% glycerol)

  • Include phosphatase inhibitors to maintain phosphorylation-dependent interactions

  • Test different detergents (NP-40, Triton X-100, CHAPS) at lower concentrations

• Advanced techniques:

  • Perform tandem affinity purification using tagged SPAC9.11

  • Implement BioID or APEX2 proximity labeling

  • Try rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME)

• Data analysis approaches:

  • Implement more sensitive mass spectrometry methods

  • Use quantitative approaches like SILAC or TMT labeling

  • Apply computational filtering to prioritize candidates

Similar approaches have been used successfully to identify transient interactions in other studies with fission yeast proteins , revealing previously unknown connections between chromatin modifiers and cellular processes.

What are the common pitfalls when using SPAC9.11 antibody in chromatin immunoprecipitation (ChIP) experiments?

Common ChIP pitfalls and solutions:

Additionally, when designing primers for ChIP-qPCR validation, ensure they target regions 80-150 bp in length with similar GC content, and always include positive control regions (regions known to be bound) and negative control regions (regions known not to be bound). Studies of chromatin-associated factors in fission yeast have demonstrated these considerations are critical for reliable results .

How can I develop a quantitative assay to measure SPAC9.11 protein levels in different genetic backgrounds or conditions?

To develop a quantitative SPAC9.11 assay:

• Quantitative Western blotting:

  • Use recombinant SPAC9.11 protein to generate a standard curve

  • Implement fluorescent secondary antibodies for wider linear range

  • Include loading controls (tubulin, actin) for normalization

  • Use digital imaging systems rather than film for quantification

• ELISA-based approach:

  • Develop a sandwich ELISA using SPAC9.11 antibody as capture antibody

  • Use a different epitope antibody or tagged version for detection

  • Include standard curves with recombinant protein

• Mass spectrometry-based quantification:

  • Implement selected reaction monitoring (SRM) or parallel reaction monitoring (PRM)

  • Use stable isotope-labeled peptide standards

  • Target unique SPAC9.11 peptides identified through preliminary discovery proteomics

• Single-cell approaches:

  • Generate fluorescent protein fusions to monitor in vivo

  • Use proximity ligation assays for protein interaction quantification

  • Consider antibody-based flow cytometry if cell permeabilization is optimized

Similar quantitative approaches have been successfully applied to measure levels of chromatin-associated proteins in yeast under different conditions , providing insights into protein dynamics during cellular processes.

How does the study of SPAC9.11 in fission yeast contribute to our understanding of chromatin regulation in higher eukaryotes?

Fission yeast research on SPAC9.11 has broader implications:

• Evolutionary conservation of chromatin mechanisms:

  • Core chromatin modification machinery is conserved from yeast to humans

  • Studies in fission yeast have revealed fundamental principles of heterochromatin formation applicable to higher eukaryotes

  • Protein-protein interactions identified in yeast often have functional counterparts in mammals

• Translational insights:

  • Chromatin regulatory mechanisms first discovered in yeast have been found to play roles in human disease

  • Understanding basic chromatin processes helps interpret genome-wide association studies

  • Yeast models provide platforms for testing chromatin-targeting therapeutics

• Technical advantages of the yeast system:

  • Genetic manipulation simplicity

  • Well-defined chromatin domains

  • Reduced genomic complexity

  • Faster generation time for experimental studies

• Specific applications to higher eukaryotes:

  • If SPAC9.11 is involved in splicing and chromatin regulation, this connects to growing evidence in mammals that chromatin structure impacts alternative splicing

  • Patterns of regulation discovered in fission yeast chromatin have informed studies of mammalian heterochromatin formation

Research on chromatin-associated factors in fission yeast has repeatedly provided foundational knowledge that has advanced understanding of chromatin biology across species .

What are the emerging technologies that could enhance SPAC9.11 antibody applications in future research?

Emerging technologies for antibody applications:

• Advanced microscopy applications:

  • Super-resolution microscopy (STORM, PALM) for precise localization

  • Live-cell antibody-based imaging using cell-permeable nanobodies

  • Correlative light and electron microscopy for ultrastructural context

• Single-cell technologies:

  • CUT&Tag for single-cell profiling of chromatin proteins

  • Single-cell proteomics combined with antibody-based enrichment

  • Spatial transcriptomics correlated with protein localization

• CRISPR-based approaches:

  • CUT&RUN or CUT&TAG using CRISPR-directed antibody recruitment

  • Combining CRISPR screens with antibody-based readouts

  • CRISPR-based tagging for orthogonal validation of antibody results

• Computational and AI integration:

  • Machine learning algorithms to predict protein-protein interactions

  • Integrative modeling of multi-omics data with antibody-derived insights

  • Automated image analysis for high-throughput antibody-based assays

• Antibody engineering advances:

  • Development of higher specificity recombinant antibodies

  • Nanobodies and single-domain antibodies for improved access to complexes

  • Proximity-dependent antibodies that only bind in specific contexts